申请人:Takeda Pharmaceutical Company Limited
公开号:US10308605B2
公开(公告)日:2019-06-04
A proton pump inhibitor containing a compound represented by the formula (I)
wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug thereof is provided.
一种质子泵抑制剂,含有由式 (I) 代表的化合物
其中 X 和 Y 相同或不同,并且各自是键或在主链中具有 1 至 20 个碳原子的间隔物,R1 是任选取代的烃基或任选取代的杂环基,R2、R3 和 R4 相同或不同,并且各自是氢原子、任选取代的烃基、任选取代的噻吩基、任选取代的苯并[b]噻吩基、任选取代的呋喃基、R5和R6相同或不同,各自为氢原子或任选取代的烃基,在体内转化为质子泵抑制剂后,具有优异的质子泵作用并显示出抗溃疡活性等,或其盐或其原药。